Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation

American Journal of Medicine

Volumn 126, Issue 7, 2013, Pages 625-632.e1

  Hess, Paul L ^a   Kim, Sunghee ^a   Piccini, Jonathan P ^a   Allen, Larry A ^b   Ansell, Jack E ^c   Chang, Paul ^d   Freeman, James V ^e   Gersh, Bernard J ^f   Kowey, Peter R ^g   Mahaffey, Kenneth W ^a   Thomas, Laine ^a   Peterson, Eric D ^a   Fonarow, Gregg C ^h  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c LENOX HILL HOSPITAL   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MAYO CLINIC   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atrial fibrillation; Evidence based medicine; Registry

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; COMORBIDITY; CORONARY ARTERY DISEASE; DEVICE THERAPY; DIABETES MELLITUS; DISEASE REGISTRY; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR;

EID: 84879154641     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2013.01.037     Document Type: Article

References (43)

1. E. Braunwald Shattuck lecture - cardiovascular medicine at the turn of the millenium: Triumphs, concerns, and opportunities N Engl J Med 337 19 1997 1360 1369
2. D.M. Lloyd-Jones, T.J. Wang, and E.P. Leip Lifetime risk for development of atrial fibrillation: the Framingham Heart Study Circulation 110 9 2004 1042 1046
3. V.L. Roger, A.S. Go, and D.M. Lloyd-Jones Heart disease and stroke statistics - 2012 update: a report from the American Heart Association Circulation 125 1 2012 e2 e220
4. V.L. Roger, A.S. Go, and D.M. Lloyd-Jones Heart disease and stroke statistics - 2011 update: a report from the American Heart Association Circulation 123 4 2011 e18 e209
5. A.S. Go, E.M. Hylek, and K.A. Phillips Prevalence of diagnosed atrial fibrillation in adults; national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study JAMA 285 2001 2370 2375
6. P.A. Wolf, T.R. Dawber, E. Thomas, and W.B. Kannel Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Heart Study Neurology 28 1978 973 977
7. E.J. Benjamin, P.A. Wolf, R.B. D'Agostino, H. Silbershatz, W.B. Kannel, and D. Levy Impact of atrial fibrillation on the risk of death: the Framingham Heart Study Circulation 98 1998 946 952
8. T.J. Wang, J.M. Massaro, and D. Levy A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study JAMA 290 2003 1049 1056
9. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation Chest 137 2 2010 263 272
10. D. Conen, C.U. Chae, and R.J. Glynn Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation JAMA 305 20 2011 2080 2087
11. A. Jahangir, V. Lee, and P.A. Friedman Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study Circulation 115 24 2007 3050 3056
12. J.P. Piccini, E.S. Fraulo, and J.E. Ansell Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF Am Heart J 162 4 2011 606.e1-612.e1
13. S.C. Smith Jr., E.J. Benjamin, and R.O. Bonow AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation Circulation 124 22 2011 2458 2473
14. M. Jessup, W.T. Abraham, and D.E. Casey 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation Circulation 119 14 2009 1977 2016
15. T.W. Rooke, A.T. Hirsch, and S. Misra 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines Circulation 124 18 2011 2020 2045
16. American Diabetes Association. Standards of medical care in diabetes - 2011 Diabetes Care 34 Suppl 1 2011 S11 S61
17. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program adult treatment panel III guidelines Circulation 110 2 2004 227 239
18. A.V. Chobanian, G.L. Bakris, and H.R. Black The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report JAMA 289 19 2003 2560 2572
19. P.L. Hess, M.A. Greiner, and G.C. Fonarow Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to medicare claims Clin Cardiol 35 11 2012 649 657
20. I.A. Nasr, A. Bouzamondo, J.S. Hulot, O. Dubourg, J.Y. Le Heuzey, and P. Lechat Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: A meta-analysis Eur Heart J 28 4 2007 457 462
21. T. Liu, L. Li, P. Korantzopoulos, E. Liu, and G. Li Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies Int J Cardiol 126 2 2008 160 170
22. M.P. Schneider, T.A. Hua, M. Bohm, K. Wachtell, S.E. Kjeldsen, and R.E. Schmieder Prevention of atrial fibrillation by renin-angiotensin system inhibition: A meta-analysis J Am Coll Cardiol 55 21 2010 2299 2307
23. K.C. Ueng, T.P. Tsai, and W.C. Yu Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation Eur Heart J 24 2003 2090 2098
24. A.H. Madrid Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study Circulation 106 3 2002 331 336
25. R.S. Williams, J.A. deLemos, V. Dimas, J. Reisch, J.A. Hill, and R.H. Naseem Effect of spironolactone on patients with atrial fibrillation and structural heart disease Clin Cardiol 34 7 2011 415 419
26. L. Fauchier, B. Pierre, A. de Labriolle, C. Grimard, N. Zannad, and D. Babuty Antiarrhythmic effect of statin therapy and atrial fibrillation: a meta-analysis of randomized controlled trials J Am Coll Cardiol 51 8 2008 828 835
27. V. Fuster, L.E. Ryden, and D.S. Cannom 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines Circulation 123 2011 e269 e367
28. G.C. Fonarow, N.M. Albert, and A.B. Curtis Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) Circulation 122 6 2010 585 596
29. P. Gaede, H. Lund-Anderson, H.H. Parving, and O. Pedersen Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 358 2008 580 591
30. L.K. Newby, N.M. LaPointe, and A.Y. Chen Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease Circulation 113 2 2006 203 212
31. S.H. Saydah, J. Fradkin, and C.C. Cowie Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes JAMA 291 3 2004 335 342
32. G.C. Fonarow, C.W. Yancy, and N.M. Albert Heart failure care in the outpatient cardiology practice setting: Findings from IMPROVE HF Circ Heart Fail 1 2 2008 98 106
33. C.A. Jackevicius, M. Mamdani, and J.V. Tu Adherence with statin therapy in elderly patients with and without acute coronary syndromes JAMA 288 4 2002 462 467
34. B.M. Egan, Y. Zhao, and R.N. Axon US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008 JAMA 303 20 2010 2043 2050
35. A.T. Hirsch, M.H. Criqui, and D. Treat-Jacobson Peripheral arterial disease detection, awareness, and treatment in primary care JAMA 286 11 2001 1317 1324
36. J. Afilalo, S. Karunananthan, M.J. Eisenberg, K.P. Alexander, and H. Bergman Role of frailty in patients with cardiovascular disease Am J Cardiol 103 11 2009 1616 1621
37. K.M. Flint, D.D. Matlock, J. Lindenfeld, and L.A. Allen Frailty and the selection of patients for destination therapy left ventricular assist device Circ Heart Fail 5 2 2012 286 293
38. K.P. Alexander, L.K. Newby, and C.P. Cannon Acute coronary care in the elderly, part I: non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology Circulation 115 19 2007 2549 2569
39. K.P. Alexander, L.K. Newby, and P.W. Armstrong Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology Circulation 115 19 2007 2570 2589
40. F. Boutitie, J.P. Boissel, and S.J. Connolly Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT investigators Circulation 99 17 1999 2268 2275
41. K.L. Thomas, S.M. Al-Khatib, and Y. Lokhnygina Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality Am Heart J 155 1 2008 87 93
42. A.S. Go, E.M. Hylek, L.H. Borowsky, K.A. Phillips, J.V. Selby, and D.E. Singer Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study Ann Intern Med 131 1999 927 934
43. P.R. Kowey, J.A. Reiffel, and R. Myerburg Warfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS registry) Am J Cardiol 105 8 2010 1130 1134